Capricor Therapeutics Faces Class Action Lawsuit Amid Share Price Plunge
Capricor Therapeutics Faces Class Action Lawsuit Amid Share Price Plunge
In the wake of alarming developments regarding Capricor Therapeutics, Inc. (NASDAQ: CAPR), a securities class action has been officially initiated by the firm Levi & Korsinsky, LLP. This legal move alarms investors who purchased shares between December 17, 2025, and July 26, 2026, after the company's stocks plummeted significantly due to negative FDA assessments related to their treatment candidate, deramiocel.
Stock Price Collapse
The downturn in Capricor’s stock value was startling, with shares nosediving from an initial high of $35.34 on April 21, 2026, to merely $4.19 by July 30, 2026. The stock saw a staggering drop of $12.70 in just one session on July 27, when it closed at $7.00, reflecting a 64% decrease. This swift decline was attributed to newly released FDA documents that indicated the ineffectiveness of their key treatment, revealing serious shortcomings in clinical efficacy.
Details of the Allegations
As disclosed in the class action complaint, the sudden correction was precipitated by two major disclosures. First, the FDA briefing documents released on July 27 stated that the results of the HOPE-3 study did not meet critical efficacy benchmarks. The documents suggested a lack of significant difference between the treatment and placebo groups after 12 months, raising severe questions regarding the treatment’s viability.
The second shock came from an advisory committee meeting held on July 29. Following this gathering, it was reported that the committee voted 9-3 against the evidence supporting the efficacy of deramiocel for treating Duchenne muscular dystrophy (DMD)-associated cardiomyopathy.
The lawsuit posits that investors were not adequately informed of Capricor's modifications to their pre-specified statistical analysis plans, which created substantial undisclosed risk while their shares traded at inflated prices.
Investor Rights and Actions
Investors who suffered losses due to these developments are encouraged to reach out to Levi & Korsinsky to determine their eligibility for recovery. The firm emphasizes that investors have until September 28, 2026, to seek lead plaintiff status, which allows them to potentially represent a larger group of aggrieved shareholders.
There are crucial FAQs related to this case that highlight significant concerns among investors:
1. What was the stock drop?
Investors saw a 78.7% decline across two corrective disclosures, totaling $15.08 per share.
2. When did misleading information occur?
The timeframe recognized as the Class Period runs from December 17, 2025, to July 26, 2026.
3. Where was the class action filed?
The complaint was filed in the United States District Court for the Southern District of California.
Ensuring Participation in the Class Action
For Capricor investors wondering how to proceed, it’s crucial to gather brokerage records showing purchase dates, quantities, and prices paid. This documentation will support any claims made during the legal proceedings. Importantly, even if shares have already been sold, investors can still pursue recovery based on their initial purchasing dates.
Levi & Korsinsky operates on a contingency basis, implying that there are no upfront costs for participating in this lawsuit. The firm does not require payments until any recovery is secured.
Conclusion
As this class action evolves, investors should stay alert to updates, especially considering the rapid changes in the landscape surrounding Capricor Therapeutics, Inc. As the situation develops further, those impacted by the sharp decline in stock value must remain proactive in seeking justice and potential compensation for their losses.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.